Can we give pembrolizumab (Keytruda) to prevent metastasis of anaplastic thyroid carcinoma after thyroidectomy?

Pembrolizumab for Prevention of Metastasis After Thyroidectomy in Anaplastic Thyroid Carcinoma

No, pembrolizumab should not be used as adjuvant therapy to prevent metastasis after thyroidectomy in anaplastic thyroid carcinoma (ATC). The current evidence and FDA approval support pembrolizumab only for treatment of metastatic or locally advanced ATC, not as adjuvant prevention therapy following complete surgical resection.

Evidence-Based Rationale

FDA-Approved Indications

The FDA label for pembrolizumab (Keytruda) does not include ATC in any setting 1. While pembrolizumab has adjuvant indications for other cancers (melanoma, NSCLC), there is no approval or established role for adjuvant use in thyroid cancer 1.

NCCN Guideline Recommendations

The 2025 NCCN Guidelines specifically address pembrolizumab use in ATC only for metastatic disease 2:

• Pembrolizumab combined with lenvatinib is recommended for patients with metastatic ATC, particularly those with:

  • Elevated tumor mutational burden (TMB)
  • PD-L1 tumor proportion score (TPS) >50%
  • The combination showed 66% complete response rate with median PFS of 16.5 months in a retrospective study 2

• Single-agent PD-1 inhibitors (pembrolizumab, nivolumab) may be used for metastatic ATC regardless of TMB or combined positive score (CPS), based on extrapolation from spartalizumab trials showing 19% overall response rate 2

Clinical Context: When Pembrolizumab IS Appropriate

Pembrolizumab should be considered in these ATC scenarios:

1. Metastatic disease at presentation - Use pembrolizumab + lenvatinib as first-line therapy 3, 4

   • Real-world data shows median OS of 7.7-10 months
   • Confirmed ORR of 36-37.5%
   • Best responses in patients with PD-L1 CPS ≥1 (present in 96% of cases) 4

2. Locally advanced unresectable disease - Consider pembrolizumab + lenvatinib to potentially downstage for surgical resection 5

   • Case reports demonstrate conversion from palliative to neoadjuvant intent
   • May enable subsequent thyroidectomy and radioiodine therapy

3. Post-operative recurrence/progression - Initiate systemic therapy when metastases develop 6

Critical Pitfalls to Avoid

Do not confuse ATC with differentiated thyroid cancer (DTC): The evidence for pembrolizumab in DTC is extremely limited to anecdotal case reports 7. ATC behaves completely differently and requires immediate aggressive systemic therapy when metastatic, not watchful waiting.

Do not delay systemic therapy in metastatic ATC: Given the extremely aggressive nature (median survival historically <6 months), pembrolizumab + lenvatinib should be initiated promptly when distant metastases are confirmed 4, 6.

Recognize that complete surgical resection in ATC is rare: Most patients (94-100%) present with metastatic disease 6. The scenario of "preventing metastasis after thyroidectomy" is uncommon because:

• ATC typically presents with advanced disease
• If truly localized and completely resected, the role becomes surveillance rather than adjuvant systemic therapy
• No evidence supports adjuvant immunotherapy in this setting

Practical Algorithm

For post-thyroidectomy ATC patients:

1. Obtain staging imaging (PET-CT, CT chest/abdomen/pelvis) within 2-4 weeks post-operatively
2. If no metastases detected: Close surveillance with imaging every 2-3 months; consider adjuvant chemoradiation for high-risk local features 2
3. If metastases detected: Initiate pembrolizumab 200mg IV Q3 weeks + lenvatinib 20mg PO daily (dose-adjusted for tolerability) 3, 4
4. Check PD-L1 status and molecular profiling: While treatment can proceed regardless, PD-L1 TPS >50% and elevated TMB predict better responses 2, 4

The evidence unequivocally supports pembrolizumab use only when metastatic disease is documented, not as preventive adjuvant therapy after complete resection.